Marloes E.C. Broekmans

Author

Vrije Universiteit Amsterdam ORCID

Also Known As

M. Broekmans, Marloes Broekmans, Marloes E. C. Broekmans, Marloes E.C. Broekmans

Publications

Citations

H-Index

Concepts

All Affiliations

Vrije Universiteit Amsterdam Amsterdam University Medical Centers University of Amsterdam Amsterdam UMC Location University of Amsterdam Janssen (United States)

About

Marloes E.C. Broekmans is an author at Vrije Universiteit Amsterdam specializing in medicine, neuro-oncology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	1.2K
2	Cell Biology	3	3	1.2K
3	Immunology	2	2	412
4	Health Sciences	1	1	28
5	Neuroscience	1	1	24

Marloes E.C. Broekmans

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
Neuroblastoma is composed of two super-enhancer-associated differentiation states Tim van Groningen, Jan Köster, Linda J. Valentijn, Nature Genetics Neuro-oncologySuper-enhancer-associated Differentiation StatesDevelopmental BiologyEpendymaNeuroblasts	2017	554
LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression Jan J. Molenaar, Raquel Domingo-Fernandéz, Marli E. Ebus, Nature Genetics Cell RegulationImmunologyLin28b InducesTumor SuppressorMedicine	2012	384
Functional MYCN signature predicts outcome of neuroblastoma irrespective of <i>MYCN</i> amplification Linda J. Valentijn, Jan Köster, Franciska Haneveld, Proceedings of the National Academy of Sciences Functional Mycn SignatureTumor BiologyNeuro-oncologyMycn ExpressionMedicine	2012	231
A NOTCH feed-forward loop drives reprogramming from adrenergic to mesenchymal state in neuroblastoma Tim van Groningen, Nurdan Akogul, Ellen M. Westerhout, Nature Communications	2019	170
Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab Jakub Krejcik, Kris A. Frerichs, Inger S. Nijhof, Clinical Cancer Research	2017	166
Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma Christie P.M. Verkleij, Marloes E.C. Broekmans, Mark van Duin, Blood Advances	2021	153
Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab Kristine A. Frerichs, Marloes E.C. Broekmans, Jhon A. Marin Soto, Clinical Cancer Research	2020	85
T-Cell Characteristics Impact Response and Resistance to T-Cell–Redirecting Bispecific Antibodies in Multiple Myeloma Christie P.M. Verkleij, Chloe O’Neill, Marloes E.C. Broekmans, Clinical Cancer Research	2024	43
Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies Christie P.M. Verkleij, Amy Jhatakia, Marloes E.C. Broekmans, Cancers	2020	35
NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma Christie P.M. Verkleij, Kristine A. Frerichs, Marloes E.C. Broekmans, HemaSphere	2023	32

Page 1